AVDL vs. MLTX, ACAD, VCEL, XENE, MOR, SWTX, MRUS, DNLI, BHC, and ZLAB
Should you be buying Avadel Pharmaceuticals stock or one of its competitors? The main competitors of Avadel Pharmaceuticals include MoonLake Immunotherapeutics (MLTX), ACADIA Pharmaceuticals (ACAD), Vericel (VCEL), Xenon Pharmaceuticals (XENE), MorphoSys (MOR), SpringWorks Therapeutics (SWTX), Merus (MRUS), Denali Therapeutics (DNLI), Bausch Health Companies (BHC), and Zai Lab (ZLAB). These companies are all part of the "pharmaceutical products" industry.
Avadel Pharmaceuticals vs.
MoonLake Immunotherapeutics (NASDAQ:MLTX) and Avadel Pharmaceuticals (NASDAQ:AVDL) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings, community ranking, media sentiment and institutional ownership.
In the previous week, MoonLake Immunotherapeutics had 6 more articles in the media than Avadel Pharmaceuticals. MarketBeat recorded 9 mentions for MoonLake Immunotherapeutics and 3 mentions for Avadel Pharmaceuticals. MoonLake Immunotherapeutics' average media sentiment score of 0.43 beat Avadel Pharmaceuticals' score of 0.42 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the media.
MoonLake Immunotherapeutics has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500. Comparatively, Avadel Pharmaceuticals has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500.
MoonLake Immunotherapeutics has a net margin of 0.00% compared to Avadel Pharmaceuticals' net margin of -52.53%. MoonLake Immunotherapeutics' return on equity of -15.54% beat Avadel Pharmaceuticals' return on equity.
MoonLake Immunotherapeutics presently has a consensus price target of $84.29, suggesting a potential upside of 78.91%. Avadel Pharmaceuticals has a consensus price target of $21.00, suggesting a potential upside of 162.50%. Given Avadel Pharmaceuticals' higher probable upside, analysts plainly believe Avadel Pharmaceuticals is more favorable than MoonLake Immunotherapeutics.
93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. Comparatively, 69.2% of Avadel Pharmaceuticals shares are owned by institutional investors. 12.0% of MoonLake Immunotherapeutics shares are owned by insiders. Comparatively, 4.8% of Avadel Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
MoonLake Immunotherapeutics has higher earnings, but lower revenue than Avadel Pharmaceuticals. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Avadel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Avadel Pharmaceuticals received 282 more outperform votes than MoonLake Immunotherapeutics when rated by MarketBeat users. However, 81.01% of users gave MoonLake Immunotherapeutics an outperform vote while only 66.28% of users gave Avadel Pharmaceuticals an outperform vote.
Summary
MoonLake Immunotherapeutics beats Avadel Pharmaceuticals on 10 of the 16 factors compared between the two stocks.
Get Avadel Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVDL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Avadel Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:AVDL) was last updated on 1/22/2025 by MarketBeat.com Staff
Free AVDL Stock Alerts